n°139

June 2013

Issue Contents
Editorial

Free  Mirage or reality?

p.144
Solid evidence is needed before approving "personalised medicine"

Marketing Authorisations

Pazopanib and soft-tissue sarcomas (New Indication)

p.145-147
Too toxic

INN common stem: -anib

p.147

Patients' interest overlooked

p.148

Eplerenone and chronic heart failure (New Indication)

p.148-149
No comparison with spironolactone

Belimumab (New Drug)

p.149
No tangible efficacy but a risk of immunosuppression

Free  Strontium ranelate for osteoporosis in men (New Indication)

p.150
More dangerous than beneficial

Exenatide added to insulin (New Indication)

p.151
Beware the potentially serious adverse effects of exenatide

Ethinylestradiol + cyproterone in France (French Withdrawal)

p.151
Good riddance

Adverse Effects

Calcium supplementation: cardiovascular risk?

p.152-153
Avoid routine calcium supplementation

Phosphate-containing eye drops: corneal opacity

p.154
Harm-benefit balance of eye drops should be reviewed regularly

Leflunomide: psoriasis, lupus

p.154
A few cases reported by EMA

Voriconazole: skeletal fluorosis

p.154
Bone pain

Tetrazepam: Lyell's syndrome and other serious disorders

p.154
Unfavourable harm-benefit balance

Reviews

Bleeding with dabigatran, rivaroxaban, apixaban

p.155-159
No antidote, and little clinical experience

Editors' Opinion

p.158
Choose warfarin

Severe COPD: oxygen prolongs survival

p.159
More than 15 hours of oxygen per day

"Antioxidants": no preventive effect against colorectal cancer

p.160
Beware self-medication

CT scans in childhood: leukaemia, brain tumours

p.160
Alternative procedures should be discussed

Outlook

Pharmacogenetics and personalised medicine: maintain a critical approach

p.161-163
Results often fall short of expectations

Genetic testing: what are the objectives?

p.162

Free  Too many unreliable guidelines

p.164
Be sceptical

Drug company influence starts at university

p.165
Subconscious and effective

Free  Facts and figures

p.166-167
Prescrire's annual financial report

Masthead

Free  Masthead

p.142

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe